Cytosorbents (CTSO) Capital Expenditures Growth (1y) (2012 - 2026)
Cytosorbents (CTSO) Capital Expenditures Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.44 Bn | 193.84 Bn | 7.27 Bn | -1.00% |
| 2 | Stryker | 127.32 Bn | 123.85 Bn | 4.50 Bn | 10.38% |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn | 6.32% |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn | 24.20% |
| 5 | Edwards Lifesciences | 51.90 Bn | 47.65 Bn | 1.35 Bn | 35.70% |
| 6 | Dexcom | 34.30 Bn | 32.36 Bn | 830.00 Mn | -9.99% |
| 7 | GE HealthCare Technologies | 33.74 Bn | 31.63 Bn | 2.18 Bn | 16.28% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | -4.32% |
| 9 | Steris | 23.05 Bn | 22.56 Bn | 684.20 Mn | -6.52% |
| 10 | Cytosorbents | 21.98 Mn | 17.56 Mn | 7.05 Mn | 106.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 106.54% |
| Mar 31, 2026 | 450.00% |
| Dec 31, 2025 | 152.17% |
| Sep 30, 2025 | -88.82% |
| Jun 30, 2025 | 107.76% |
| Mar 31, 2025 | -95.57% |
| Dec 31, 2024 | -138.47% |
| Dec 31, 2023 | 109.76% |
| Dec 31, 2022 | -251.43% |
| Sep 30, 2022 | 563.68% |
| Jun 30, 2022 | -160.92% |
| Mar 31, 2022 | 65.70% |
| Dec 31, 2021 | 2,147.60% |
| Sep 30, 2021 | -629.52% |
| Jun 30, 2021 | 874.08% |
| Mar 31, 2021 | 81.97% |
| Dec 31, 2020 | 15.10% |
| Sep 30, 2020 | 81.91% |
| Jun 30, 2020 | -41.58% |
| Mar 31, 2020 | -19.46% |